logging in or signing up New Drug Delivery System shraddha5j Download Post to : URL : Related Presentations : Let's Connect Share Add to Flag Embed Email Send to Blogs and Networks Add to Channel Copy embed code: Embed: Flash iPad Dynamic Copy Does not support media & animations Automatically changes to Flash or non-Flash embed WordPress Embed Customize Embed URL: Copy Thumbnail: Copy The presentation is successfully added In Your Favorites. Views: 1166 Category: Entertainment License: All Rights Reserved Like it (0) Dislike it (0) Added: September 21, 2011 This Presentation is Public Favorites: 0 Presentation Description No description available. Comments Posting comment... Premium member Presentation Transcript Slide 1: 1 New Drug Delivery Systems Maharukh Rustomjee Founder and Chief Operating Officer Rubicon Research Pvt. Ltd. Email: email@example.com A Global Opportunity BIOINVEST 2007 - MUMBAI - NOV 01 & 02, 2007Overview: 2 Overview Product Development Cycle Role of Drug Delivery Systems in Product Life Cycle New Drug Delivery Systems Business opportunity Case studies NDDS Partnership Model Advantage India NDDS at Rubicon ResearchNew Drug Discovery And Development Process: 3 New Drug Discovery And Development Process (source:www.montrealinternational.com) DDS DDS Getting a suitable drug delivery form is almost as important as the drug itselfDeclining R&D Productivity: 4 Declining R&D Productivity R&D spend vs. NMEs approved Cost per NME approved So. PhRMA, US FDA Global players looking for an alternatives to increase productivityRole of Drug Delivery Systems in R&D: 5 Role of Drug Delivery Systems in R&D NDDS – is now considered from the earliest development stage Novel Drug Delivery Systems ENABLING New Molecules New drug New DDS New drug Proven DDS ENHANCING Life Cycle Management Proven drug New DDS Proven drug Proven DDS V A L U E & R I S KDrug Delivery Systems – Strategic Tool: 6 Drug Delivery Systems – Strategic Tool N D D S Scientific Meet clinical need Optimize PK profile Reduce Side effects Delivery by conventional route Improved compliance Business Patent/ Exclusivity Competitive Advantage Market Penetration Market image New patient population NDDS offers benefits to patients, clinicians and pharmaceutical industrySlide 7: 7 Desired Aspects of Drug Delivery Systems Commercial Success PATIENT BENEFIT Minimum regulatory barriers Opportunity for IP Cost Effective Commercially viableNew Drug Delivery Systems (NDDS) Market: 8 Source : 1 – IMS Health 2 – Pharmacircle 3 – Company Annual Reports New Drug Delivery Systems (NDDS) Market Global pharmaceutical - $555.5 billion in 2006 1 ~ $72 billion (~13%) is accounted for drugs incorporating NDDS 1 NDDS market has a CAGR of ~15% v/s ~6% CAGR of global pharmaceutical market There are 700 NDDS companies with more than 1700 technologies 2 Worldwide NDDS market ten times Indian Pharma marketNDDS - Market Segment: 9 Segment wise share of NDDS –expected in 2007 NDDS - Market Segment Oral Controlled Release Systems continues to dominate NDDS Source: FrontLine strategic Consulting Inc. 2002Applications of NDDS: 10 Applications of NDDS Need Technology Drug Benefit Pharmacokinetic Profile of Drugs PEgylation Filgrastin (Neulasta) Prolongs the length of time the drug stays in the body, and allows for administration in a single dose Window of Absorption Gastroretentive - Metformin (Glumetza) Tablets retained in the stomach for > 6hrs Side Effects OROS system Oxybutinin (Ditropan XL) Reduced 1 st pass effect, lesser metabolites, less side effects Timed Delivery Pulsatile Release System Verapamil 24H Blood pressure control Drug Targeting Targit Mesalazine Local action : reduced side effects, reduced doseCase Study – LCM of an old drug: 11 Case Study – LCM of an old drug Brand Name Marketed By Technology Patent Status Concerta Alza OROS® Patented technology Ritalin SR Novartis Matrix Non- Infringing technology Ritalin LA Novartis SODAS® Licensed from Elan Metadate Celltech Diffucaps® Licensed from Eurand Focalin XR Novartis Pure isomer Patented technology Route of administration – Oral Alternate Route – Transdermal , Daytrana® by Shire Methylphenidate – an example of multiple technologies, dosage forms, route of administrationCase Study – Life cycle management : 12 Case Study – Life cycle managementMarketed by Genentech using technology of Alkermes Injection SR formulation of human growth hormone Children deficient in Growth Harmone – Receives injection for years until completion of puberty. Once a month or twice a month dosage form highly desired Nutropin depot was developed using ProLease® Technology comprising of biodegradable polymeric microspheres. : 13 Marketed by Genentech using technology of Alkermes Injection SR formulation of human growth hormone Children deficient in Growth Harmone – Receives injection for years until completion of puberty. Once a month or twice a month dosage form highly desired Nutropin depot was developed using ProLease® Technology comprising of biodegradable polymeric microspheres. Case Study-BioNDDS: Nutropin Depot Case Study-BioNDDS : Permeability Enhancement : 14 Emisphere has designed and synthesized >1800 delivery agents to facilitate delivery of therapeutic agents. Technology enables to select and customize delivery agents to facilitate the oral delivery of broad range of actives. e.g. Heparin. Case Study-BioNDDS : Permeability EnhancementPartnership Model: 15 Partnership Model Typical Business Model Out licensing model Fee for service model Risk sharing model Revenue Components R&D collaboration revenues ( Development Fees) License fees/ milestone payments / Royalties Material Sales Manufacturing Revenues Drug delivery companies develop technologies Create business with this assetReasons for Partnership: 16 Reasons for Partnership Parameters that companies look at during their DDS partner selection process: Average ratings on a scale of 0 - 9 So. E&Y Survey, 2007Key Criteria for Successful NDDS Partnership : 17 clinical end points NDDS Company Concept feasible IP strength regulatory path cost & timeframe safety issues Customers need Pharmaceutical Marketing company competitive landscape Freedom to Operate? market size cost of goods sold Acceptable ROI Key Criteria for Successful NDDS Partnership Are we comfortable working together ? Do our company’s share the same long term ideology on the product partnership ?NDDS Partnership Success Stories: 18 NDDS Partnership Success Stories Drug NDDS DDS COMPANY Pharma company Peak Sales USD Bn Duragesic Transdermal Patch Alza Janssen 2.08 (2004) Wellbutrin XL ER tablet Bioavail GSK 1.84 (2006) Lupron Injectable Depot TAP TAP 1.10 (2002) Procardia XL OROS Alza Pfizer 1.18 (1994) Cardizem SR/CD ER tablet Elan Aventis 1.01 (1999) Source : Specialty Pharma Jul/Aug 2006 Vol.2 No.4NDDS Partnership Success Stories: 19 NDDS Partnership Success Stories Drug NDDS DDS company Pharma company Deal in USD Mn Cipro OD ER tablet Ranbaxy < 65 (1999) Keppra Extended release tablets Alembic 11 (2007) Trambex Mouth Dissolving Tablets Ethypharm In Licensing (2006) Not Disclosed CDT technology SCOLR Not Disclosed Source : Internet Bayer UCB Ranbaxy DRLNDDS Partnership - Advantage India: 20 Signatory to WTO, acceptance of IPR Proven scientific talent pool No language barrier Cost effective Established regulatory skills India has highest number of US-FDA approved facilities outside USA Indian players account for about 25-30% of the total DMFs filed with the US FDA NDDS Partnership - Advantage India A number of Indian companies have developed various DDSSlide 21: 21 Identification of unmet therapeutic need Determining novel technologies to meet the need Product with desired therapeutic benefits DEVELOPED SEVERAL TECHNOLOGIES BASED ON THIS APPROACH R&D Initiatives at Rubicon ResearchDDS Technologies of Rubicon Research: 22 DDS Technologies of Rubicon Research RubiEn TM - Bioenhanced Drug Delivery System RubiODT TM - Orally Disintegrating Tablet RubiDT TM - Novel Dispersible Tablet RubiReten TM - Gastroretentive Solubilised Drug Delivery System RubiCoat TM - Aqueous Wax Coating System RubiERT TM - Extended Release Tablet RubiXcip TM - Novel Multifunctional ExcipientSlide 23: 23 The true potential (Significance) of drug delivery technologies lies in their ability to improve the safety, efficacy and medical utility of several drugsSlide 24: 24 THANK YOU You do not have the permission to view this presentation. In order to view it, please contact the author of the presentation.